BIOCYTOGEN
15.9.2022 14:03:42 CEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell therapy platform.
Biocytogen’s TCR-mimic antibody development platform utilizes its proprietary fully human antibody RenMiceTM (RenMabTM and RenLite® mice) that have been further engineered to express a human leukocyte antigen (HLA) gene. Antibodies against intracellular tumor-associated antigens are subjected to advanced high-throughput antibody screening technologies to discover antibodies with high specificity and affinity.
“Most tumor antigens are intracellular, and our TCR-mimic platform provides a solution for developing antibodies against these valuable targets,” said Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen. “TCR-mimic antibodies generated by our TCR-mimic platform have potentials to be developed into multiple drug modalities such as T cell engagers, bispecific/multispecific antibodies and CAR-T therapies. We are pleased to collaborate with FineImmune to explore the application of our antibodies in the field of cell therapies.”
FineImmune is a pioneering T cell therapy company, and has solved multiple critical barriers in the microenvironment of solid tumors by using multiple proprietary technology platforms, such as GSOP for T-cell engineering, HAP for TCR identification, CMP for personalized TCR-T cell production and in vivo T-cell delivery platform (TDP). FineImmune’s product pipelines include TCR-T, CAR-T, TAL, TIL, etc. The company developed the first personalized neoantigen-specific TCR-T cell therapy, which is in phase I clinical trial now. In addition, FineImmune possesses technologies for the precision prediction of the efficacy and side effects of immunotherapy, enabling healthcare professionals to provide effective and safe immunotherapy to patients with common malignant tumors.
“T cells play an important role in treating cancers. Biocytogen’s advanced TCR-mimic platform makes it possible for us to develop T cell therapies against crucial but low-expressed intracellular tumor antigens,” said Dr. Penghui Zhou, Founder and Chief Technology Officer of FineImmune. “We focus on providing efficient and safe immunotherapy using advanced technologies. This collaboration will promote the development of new cell therapeutic drugs and the expansion of the potential of immunotherapy to benefit patients.”
About the TCR-Mimic Platform
Biocytogen’s T Cell Receptor (TCR)-Mimic platform utilizes HLA-expressing fully human antibody mice (HLA/RenMice) to generate antibodies to intracellular tumor-associated antigens when immunized with MHC-antigen-peptide complexes. Subsequently, Biocytogen’s high-throughput antibody screening platform aims to swiftly identify TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients. Currently, antibody sequences against multiple intracellular targets have been obtained, and their efficacies have been verified in vitro and in vivo. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and/or best-in-class antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. On September 1, 2022, Biocytogen was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 02315.HK. For more information, please visit http://en.biocytogen.com.cn.
About FineImmune
Guangzhou FineImmune Biotechnology Co., Ltd. is an innovation driven company based in China. The company is mainly engaged in the development of solid tumor immunotherapy drugs and related businesses. It has solved key technical bottlenecks in solid tumor immunotherapy and possesses core technologies. A number of T-cell therapy products for solid tumors are in clinical trials, as well as diagnostic reagents for accurate identification of effective populations. It has a 2000 square meter immunotherapy R&D laboratory and a GMP production workshop for cell therapy products in Guangzhou Science City. The company's individualized TCR-T cell therapy product (new drug) has been carried out clinical research in the Affiliated Tumor Hospital of Sun Yat sen University. At present, more than 20 immune cell therapy products and technologies are under research and development. For more information, please visit http://www.fineimmu.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005284/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply and the University of Milan Launch Experimental Research on Biological Computing Based on Cortical Labs’ CL1 Platform28.1.2026 15:10:00 CET | Press release
Reply [EXM, STAR: REY] today announced the start of a collaboration with the Department of Pathophysiology and Transplantation of the University of Milan, together with the “Centro Dino Ferrari” of the University of Milan - Ospedale Policlinico, for a new research and experimental initiative in the field of biological computing. The project aims to explore innovative approaches to learning and information processing through the integration of biological systems and digital technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128715625/en/ This initiative represents the starting point of an advanced research programme aimed at exploring new computational paradigms. At the core of the initiative is the CL1 biological computer developed by Cortical Labs, an Australian biotechnology company. Unlike conventional silicon-based computing architectures, this technology leverages the processing capabilities of living human
Brown Brothers Harriman Investor Services and SimCorp Forge Strategic Alliance to Provide Integrated End-to-End Technology, Data, and Services Solution for Global Asset Managers28.1.2026 15:00:00 CET | Press release
New offering leverages BBH Infomediary® to combine the benefits of the SimCorp One enterprise platform, including SimCorp Managed Business Services, with BBH Investor Services’ fund servicing and custody product suite. BBH Infomediary used to integrate BBH and SimCorp’s platforms and to connect to third parties in a unique open architecture model. Addresses the needs of global asset managers seeking to streamline and modernize their operating model. Quoniam Asset Management, a leading systematic manager, is the first to benefit from this data-driven offering. Brown Brothers Harriman (BBH), a privately held global financial services firm, and SimCorp, a leading global financial technology company, today announced a new strategic alliance to address the needs of global asset managers requiring an integrated, end-to-end technology, data, and services solution. Enhancing both firms’ existing offerings, this solution uses BBH Infomediary to integrate SimCorp One’s front and middle office ca
Wunderkind Joins Klaviyo Marketplace, Bringing Identity-Based Personalization and Revenue Growth to E-Commerce Brands28.1.2026 15:00:00 CET | Press release
New integration unlocks greater site identification, real-time personalization, and scalable triggered messaging Wunderkind, the AI decisioning platform that delivers identity resolution and cross-channel personalization to scale performance and reach, today announced its official debut on the Klaviyo App Marketplace. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128210560/en/ The integration brings Wunderkind’s identity insights directly into Klaviyo’s B2C CRM, powering real-time profiles, segments, and flows that help brands recognize more customers earlier in the journey and deliver relevant experiences across email, SMS and other Klaviyo-powered channels. By layering Wunderkind’s industry-leading Identity Network — built on more than 9 billion device profiles and over a billion unique user identities — into Klaviyo’s unified customer profile, marketers can strengthen their understanding of who customers are, unify id
Geoprofessionals Spend a Quarter of Their Time Managing Data and Are Increasingly Turning to AI, Reveals New Seequent Survey28.1.2026 15:00:00 CET | Press release
Mining and civil geoprofessionals rate data management as highly/critically important but face big challenges unlocking value from complex datasets Seequent, the Bentley Subsurface company, says mining and civil geoprofessionals turning to AI still struggle to unlock value from increasingly complex, multisource datasets, according to its 7th Geoprofessionals Data Management Report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128879634/en/ Geoprofessionals spend a quarter of their time managing data and are increasingly turning to AI, reveals new Seequent survey. The global report, based on a survey of more than 1,000 geoprofessionals worldwide, highlights teams grappling with complex datasets across multiple software platforms, unmanaged historical data, and significant time spent on routine data administration. Angela Harvey, Chief Customer Officer, Seequent, said: ‘According to the report findings, geoprofessionals o
WeFi Technology Group Announces Partnership with PGA Tour Rising Star28.1.2026 14:40:00 CET | Press release
Shared values of vision, competitiveness, and ambition underscore multi-year partnership with the 2025 PGA Rookie of the Year. WeFi Technology Group, a global provider of technology-enabled working capital solutions, today announced a multi-year brand partnership with Aldrich Potgieter, the 2025 PGA Tour Rookie of the Year and one of the most promising young players on the international golf circuit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128340648/en/ Aldrich Potgieter, 2025 PGA Tour Rookie of the Year and one of the most promising young players on the international golf circuit. Leveraging its AI-powered platform, WeFi Technology operates at the intersection of finance, technology, and innovation in over 40 countries around the globe, delivering working capital solutions that drive client growth. Potgieter rose to global prominence at just 19 years old when he became the youngest winner in Korn Ferry Tour histor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom